ArticleInfectious agents and cancer2013
c-Met inhibitors.
Article in Infectious agents and cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Upconversion nanoplatform unlocks the theranostic potential of Lu-177 radiotherapy via c-MET axis targeting in head and neck squamous cell carcinoma.Materials today. Bio · 2026Article
- Medicinal Chemistry of Small-Molecule c-Met Inhibitors: From Approved Therapies to Emerging Multitarget Anticancer Agents.International journal of molecular sciences · 2026Review
- Orthogonal MET analysis in a population-representative stage II-III colon cancer cohort: prognostic and potential therapeutic implications.Molecular oncology · 2021Article
- Discovery of an Indirubin Derivative as a Novel c-Met Kinase Inhibitor withBiomolecules & therapeutics · 2019Article
- Safety and Tolerability of c-MET Inhibitors in Cancer.Drug safety · 2019Review
- Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.Cancer biology & therapy · 2017Article
- DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.International journal of oncology · 2017Article
- SU11274 suppresses proliferation and motility of pancreatic cancer cells.Oncology letters · 2015Article
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.Investigational new drugs · 2015Article
- C-MET overexpression and amplification in gliomas.International journal of clinical and experimental pathology · 2015Article
- Co-culture of hepatocellular carcinoma cells and human umbilical endothelial cells damaged by SU11274.Biomedical reports · 2014Article
- The role of Wnt signaling pathway in carcinogenesis and implications for anticancer therapeutics.Hereditary cancer in clinical practice · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.